ACCEL Lite: ACC.22 Late Breaker: ADAPT-TAVR Trial -- Edoxaban Versus DAPT For Valve Thrombosis And Cerebral TE After TAVR

May 24, 2022   |  Alison Bailey, MD, FACC; Sun Moon Kim, MD, FACC; Zaid Almarzooq, MD; Duk-Woo Park, MD, PhD, FACC

Podcast

Font Size
A
A
A

What is clinical problem with regard to leaflet thrombosis after TAVR, and what are the main findings of the ADAPT-TAVR trial?

In this interview, Duk-Woo Park, MD and Sun Moon Kim MD, with Zaid I. Almarzooq MBBCh, discuss Late Breaker: Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial.

Related References:

  1. Bogyi M, Schernthaner RE, Loewe C, et al. Subclinical leaflet thrombosis after transcatheter aortic valve replacement. JACC: Cardiovascular Interventions. 2021;14:2643-2656. doi: doi:10.1016/j.jcin.2021.09.019.
  2. Chakravarty T, Sondergaard L, Friedman J, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: An observational study. Lancet. 2017;389:2383-2392. doi: 10.1016/s0140-6736(17)30757-2.



Clinical Topics: Cardiac Surgery, Invasive Cardiovascular Angiography and Intervention

Keywords: ACCELLite, Transcatheter Aortic Valve Replacement


< Back to Listings